Anixa Biosciences completes IND transfer, advances breast cancer vaccine to Phase 2 trial.

Anixa Biosciences has completed the transfer of the Investigational New Drug application for its breast cancer vaccine from Cleveland Clinic, becoming the trial sponsor for future development. Enrollment is complete, with encouraging immune response and safety data observed in the Phase 1 trial. The company plans to advance the vaccine into a Phase 2 clinical trial and utilize multiple clinical sites, including Cleveland Clinic.